TD Cowen raised the firm’s price target on Novo Nordisk (NVO) to $135 from $115 and keeps an Outperform rating on the shares. The firm noted they announced it is acquiring 3 fill/finish sites from Catalent (CTLT) for $11B which should gradually increase production capacity beginning in 2026. This deal will likely boost production faster and signals confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- M & A News: Novo Nordisk Announces $16.5B Catalent (NYSE:CTLT) Deal
- Catalent jumps 13% to $61.46 after Novo Holdings merger agreement
- Novo Holdings to sell three Catalent fill-finish sites after merger
- Skye Bioscience initiated with an Overweight at Piper Sandler
- Novo Holdings to acquire Catalent for $63.50 per share in cash, or $16.5B
